Advicenne Pharma has a Scientific Committee tasked with assisting the management in identifying new products, defining the requirements for children or for orphan diseases, challenging development plans and the strategies for regulatory registration.
Scientific Committee Members
Dr Pierre Attali: Deputy CEO, Strategy and Medical Affairs for BioAlliance. Expert in clinical research (Synthelabo) . Practitioner in the hospitals of Bicêtre and Paul Brousse (AP-HP), and as such principal investigator for several clinical trials into liver diseases.
Françoise Brunner-Ferber: Expert in the field of animal and human pharmacology for the development of innovative drugs. More than 20 years’ experience in key posts in the pharmaceutical industry (Johnson & Johnson, Marion Merell Dow, Hoechst Marion Roussel, Aventis).
Dr Catherine Chiron, MD, PhD is a Pediatric Neurologist, specialist in the clinical pharmacology of anti-epileptic drugs in children. Dr Chiron is Director of the INSERM Research Unit 663 (Children Epilepsy & Cerebral Plasticity) at Necker Hospital and University Paris Descartes, Paris, and pediatric neurologist at “Assistance Publique-Hôpitaux de Paris”.
Dr Pierre Cochat: Pediatric Nephrology, Head of the Pediatrics Department – Hôpital Edouard Herriot, Lyon
ADV7103 is an innovative formula presented as micro-tablets to treat an orphan renal disease. (Orphan and PUMA status)